ORPHA:93108
Renal dysplasia
Also known as: Kidney dysplasia
Publications
5,629
92.2th percentile
Trials
2
Interventional, condition-specific
Researchers
1,186
Distinct authors in sample
Gene link
UPK3A
Limited
Readiness
4/6
Stages with a signal
Clinical definition (Orphanet)
A rare renal in which the kidney(s) are present but their development is abnormal, leading to of histologic architecture of the kidney and presence of embryological tissue such as mesenchymal collarettes or other forms of undifferentiated and metaplastic tissues. Renal can be unilateral or bilateral, segmental, and of variable severity.
How rare: 1-5 / 10 000 — about one to five people per ten thousand (still uncommon, but less ultra-rare).
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0019638
- UMLS:C3536714
Additional Mondo synonyms (2)
renal dysplasia · renal dysplasia (disease)
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
4/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedPresent
Limited — UPK3A
- LiteraturePresent
5,629 matched papers (2,952 in last 10 years) Source
- Phenotype characterisedPresent
28 HPO annotations (e.g. Multicystic kidney dysplasia; Abnormal nephron morphology; Chronic kidney disease) Source
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialPresent
2 matched on ClinicalTrials.gov (1 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Possibly — only limited evidence so far for UPK3A.
GenCC classification: Limited.
Phenotypes (Monarch / HPO)
28
Associated phenotypes · MONDO:0019638
- Multicystic kidney dysplasia
- Abnormal nephron morphology
- Chronic kidney disease
- Recurrent urinary tract infections
- Pyelonephritis
Showing 5 of 28 — open Monarch for the full list.
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
No drugs or clinical candidates returned for this Mondo ID on Open Targets.
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
5,629
5,629 papers — among the better-studied rare conditions, though still a fraction of common-disease literature (breast cancer: over 700,000). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
5,629 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
2,952 in the last 10 years · high confidence · 92.2th percentile (publications denominator)
Phrase hits: 5,072 · MeSH hits: 0
Who's working on it?
1,186
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Li Y8 papers · 2026
Department of Prenatal Diagnosis, Jinan Maternal and Child Health Hospital, Jinan 250001, Shandong Province, China.
Papers in Europe PMC - 02Liu J5 papers · 2026
Biochip Laboratory, Yantai Yuhuangding Hospital Affiliated to Qingdao University, Yantai, Shandong, China.
Papers in Europe PMC - 03Wang H5 papers · 2025
Department of Nephrology, Key Laboratory of Major Diseases in Children, Ministry of Education, Beijing Children's Hospital, National Center for Children's Health, Capital Medical University, Beijing, 100045, China. wanghui@bch.com.cn.
Papers in Europe PMC - 04Zhang C5 papers · 2026
Department of Oncology, Anhui Chest Hospital, Hefei, Anhui, China.
Papers in Europe PMC - 05Zhang Y5 papers · 2026
Department of Obstetrics and Gynecology, Nanfang Hospital, Southern Medical University, 1838 Guangzhou Avenue North, Guangzhou, 510515, China.
Papers in Europe PMC - 06Zhao X5 papers · 2025
Department of Pharmacology, Basic Medical School of Wuhan University, Wuhan, 430071, China.
Papers in Europe PMC - 07
- 08Jiang X4 papers · 2025
Department of Obstetrics and Gynecology, Nanfang Hospital, Southern Medical University, 1838 Guangzhou Avenue North, Guangzhou, 510515, China.
Papers in Europe PMC - 09Li S4 papers · 2026
Department of Endocrinology and Metabolism, Tianjin Medical University General Hospital, Tianjin, China.
Papers in Europe PMC - 10Peycelon M4 papers · 2026
Department of Pediatric Surgery and Urology, National Reference Center for Rare Urinary Tract Malformations (CRMR MARVU), ERN eUROGEN, Robert-Debré University Hospital, APHP, GHU North, Université Paris Cité, 48, Boulevard Sérurier, 75019, Paris, France. matthieu.peycelon@aphp.fr.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
2
interventional trials for this specific condition
2 interventional trials matched this specific condition name; 1 currently recruiting in our sample.
Data as of 11 September 2026 · last trial check 28 July 2026
2 interventional trials — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 84.5th percentile).
high confidence · 84.5th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
2 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT06728228·RECRUITING·Amnioinfusion for Fetal Renal Failure
Not reviewed·Conditions: Multicystic Dysplastic Kidney · Polycystic Kidney Disease · Fetal Renal Anomaly · Anhydramnios·Matched via name phrase
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 48 · after dedupe 48 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 48 · dropped 0 · fetched 2026-07-30
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (48)
- isrctn·ISRCTN24585341·No longer recruiting·Combining maximized ("proximal") brain protection in percutaneous treatment of carotid artery narrowings with stents designed to trap the atherosclerotic plaque: a study of brain injury
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN16819837·Recruiting·The use of CARBALIVE in the treatment of cholestatic liver disease
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN74302277·No longer recruiting·Effectiveness of nebulized hypertonic saline in mild-to-moderate bronchiolitis
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN13727659·Recruiting·Tranexamic acid to prevent anastomotic leak after rectal cancer surgery
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN12358813·Recruiting·Asp-PSC: effect of aspirin on reducing cancer & improving outcomes in primary sclerosing cholangitis
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN15936332·No longer recruiting·Phase 2b efficacy and safety study of JNJ-77242113 in participants with ulcerative colitis
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN72579770·No longer recruiting·Acetaminophen versus ibuprofen in the management of hemodynamically significant patent ductus arteriosus in very low birth weight infants
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN57876689·No longer recruiting·A prospective clinical evaluation of the Trident II 3D printed acetabular component in total hip replacement patients
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN16103145·No longer recruiting·Injection of IP-001 into thermally ablated solid tumors
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN13526628·Recruiting·COLO-PREVENT – do simple drugs (aspirin or aspirin plus metformin) or food supplements (resveratrol) reduce the occurrence of bowel polyps (small growths on the bowel lining), which in turn reduce bowel cancer risk?
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN80103507·No longer recruiting·A clinical trial to see if a mesenchymal stem cells treatment called ORBCEL-C™ can help to treat primary sclerosing cholangitis, rheumatoid arthritis, lupus nephritis and Crohn’s disease
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN83842641·Recruiting·A trial assessing preoperative chemotherapy in patients with locally advanced but operable colon cancer
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN81162400·No longer recruiting·Plasma cell depletion for Graves’ disease trial
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN91554748·No longer recruiting·To evaluate the clinical outcome of a ceramic-on-ceramic hip resurfacing arthroplasty using the ceramic, non-porous, non-cemented H1 Hip Resurfacing Arthroplasty
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN15066737·No longer recruiting·The exploration of the differences between two surgical approaches in total hip arthroplasty, direct anterior minimal invasive surgery and Hardinge’s approach, in obese and non-obese hip osteoarthritic patients
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN37815869·No longer recruiting·Repurposing carbamazepine for treatment of skeletal dysplasia in children
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN14296856·No longer recruiting·Efficacy and safety of oral BT-11 in mild to moderate ulcerative colitis
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN14513591·No longer recruiting·Is the use of digital pathology in routine diagnosis reliable and safe in comparison to standard microscopy?
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN15410818·No longer recruiting·Investigating the impact of Maraviroc on liver inflammation in patients with HIV and fatty liver disease
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN73586959·No longer recruiting·Selected mesenchymal stromal cells to reduce liver inflammation
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN43717130·No longer recruiting·Randomised double blind clinical trial in acute severe colitis: The IASO Trial
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN12067514·No longer recruiting·Reduced Fetal Movement Intervention Trial (ReMIT-2)
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN82045842·No longer recruiting·Randomised study comparing the metal ions released from two different hip resurfacing devices
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN12302923·No longer recruiting·Patent ductus arteriosus (PDA) treatment in premature infants
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN47873003·No longer recruiting·Belimumab after B Cell depletion therapy as a new treatment for patients with systemic lupus erythematosus (SLE)
skipped — LLM skipped (--skip-llm)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Renal dysplasia — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
("Renal dysplasia" OR "Kidney dysplasia" OR "renal dysplasia (disease)") OR ("UPK3A" OR "UPK3A syndrome" OR "UPK3A-related")ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Renal dysplasia" OR "Kidney dysplasia" OR "renal dysplasia (disease)"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 2 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T04:06:10.520Z
